---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009147"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T12:50:17.052260+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress

## Summary
- $25M payment received Jan 30, 2024, under global licensing agreement with BMS.
- Triggered by dosing of first patient in phase 2 dose expansion of CA115-001 trial of BMS-986442.
- This is the second development milestone under the agreement; first achieved previously.
- Payment was received on January 30, 2024, as confirmed by the filing.

## SEC filing metadata
- accession: 0000950170-24-009147
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/0000950170-24-009147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017024009147/agen-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009147
- JSON: https://secwatch.observer/filing/0000950170-24-009147.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.